1706528-83-7
Chemical Structure
Treprostinil palmitil
Synonym(s): INS-1009
- CAS No.: 1706528-83-7
- Formula:C39H66O5
- Molecular Weight:614.94
IUPAC Name: hexadecyl 2-(((1R,2R,3aS,9aS)-2-hydroxy-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl)oxy)acetate
InChIKey: XOKCXRVJBBLBSX-HDMCCQRMSA-N
SMILES: CCCCC[C@H](O)CC[C@@H]1[C@]2([H])[C@@](C[C@H]1O)([H])CC3=C(OCC(OCCCCCCCCCCCCCCCC)=O)C=CC=C3C2
Biological Activity: Treprostinil palmitil is a long-acting inhaled pulmonary vasodilator prodrug of Treprostinil (HY-100441), formulated in a lipid nanoparticle (LNP). Treprostinil palmitil can inhibit pulmonary vascular remodeling induced by Su/Hx challenge in rats. Treprostinil palmitil can induce cough. Treprostinil palmitil demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo. Treprostinil palmitil can be studied in research for pulmonary arterial hypertension and interstitial lung disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Treprostinil palmitil | 99.62% | Treprostinil palmitil is a long-acting inhaled pulmonary vasodilator prodrug of Treprostinil (HY-100441), formulated in a lipid nanoparticle (LNP). Treprostinil palmitil can inhibit pulmonary vascular remodeling induced by Su/Hx challenge in rats. Treprostinil palmitil can induce cough. Treprostinil palmitil demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo. Treprostinil palmitil can be studied in research for pulmonary arterial hypertension and interstitial lung disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Treprostinil palmitil (Standard) | ≥98% | Treprostinil palmitil (Standard) is the analytical standard of Treprostinil palmitil (HY-109163). This product is intended for research and analytical applications. Treprostinil palmitil is a long-acting inhaled pulmonary vasodilator prodrug of Treprostinil (HY-100441), formulated in a lipid nanoparticle (LNP). Treprostinil palmitil can inhibit pulmonary vascular remodeling induced by Su/Hx challenge in rats. Treprostinil palmitil can induce cough. Treprostinil palmitil demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo. Treprostinil palmitil can be studied in research for pulmonary arterial hypertension and interstitial lung disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Treprostinil palmitil-d4 | Treprostinil palmitil-d4 (INS-1009-d4) is the deuterated-labeled Treprostinil palmitil (HY-109163). Treprostinil palmitil is a long-acting inhaled pulmonary vasodilator prodrug of Treprostinil (HY-100441), formulated in a lipid nanoparticle (LNP). Treprostinil palmitil can inhibit pulmonary vascular remodeling induced by Su/Hx challenge in rats. Treprostinil palmitil can induce cough. Treprostinil palmitil demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo. Treprostinil palmitil can be studied in research for pulmonary arterial hypertension and interstitial lung disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chapman RW, Corboz MR, Malinin VS, Plaunt AJ, Konicek DM, Li Z, Perkins WR. An overview of the biology of a long-acting inhaled treprostinil prodrug. Pulm Pharmacol Ther. 2020 Dec;65:102002. [Content Brief]
- [2]. Corboz, M. R., et al., (2022). Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. The Journal of pharmacology and experimental therapeutics, 383(1), 103–116. [Content Brief]
- [3]. Chapman, R. W., et al., (2021). Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil. ERJ open research, 7(1), 00592-2020. [Content Brief]
- [4]. Plaunt, A. J., et al., (2021). Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension. International journal of molecular sciences, 22(2), 548. [Content Brief]
